



SmartPA Criteria Proposal

Drug/Drug Class:	Bone Ossification Agents PDL Edit
First Implementation Date:	December 16, 2004
Revised Date:	October 14, 2021
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: The bisphosphonates act primarily on bone through inhibition of normal and abnormal bone resorption. This group of agents has an affinity for hydroxyapatite crystals in bone and induces the inhibition of osteoclast activity. They also decrease the number of available osteoclasts by inhibiting enzymes in the mevalonate pathway, which then prevents the prenylation of proteins that are necessary for osteoclast formation. Studies have demonstrated the ability of these agents to decrease bone resorption without impairing bone mineralization or interfering with bone formation. Bisphosphonates administered orally have been associated with dysphagia, esophagitis, and esophageal or gastric ulcers. Therefore, these agents should not be given to participants with any active upper gastrointestinal disease and should be discontinued in those who develop symptoms of esophagitis. Bisphosphonates are most commonly used for the treatment and prevention of osteoporosis in postmenopausal women. Prior to treatment with bisphosphonates, participants should be tested for other possible contributors to osteoporosis such as hypocalcemia, vitamin D deficiency, and renal impairment. Bisphosphonates are also used to treat hypercalcemia, Paget disease, and malignancies including multiple myeloma, breast cancer, and prostate cancer. There are both intravenous and orally available formulations of bisphosphonates. The adverse effect of flu-like symptoms is specific to the intravenous route of administration. Adverse effects that may occur with both intravenous and oral routes are hypocalcemia, musculoskeletal pain, renal, ocular side effects, atrial fibrillation, osteonecrosis of the jaw, and atypical femur fractures.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> Alendronate Tabs Ibandronate 	<ul style="list-style-type: none"> Actonel® Alendronate Soln Atelvia® Boniva® Calcitonin Salmon Nasal Spray Etidronate Fosamax® Fosamax Plus D® Risedronate Risedronate DR

- Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit
- Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Bone Ossification Agents
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 2 or more preferred agents
 - Documented trial period of preferred agents **OR**
 - Documented ADE/ADR to preferred agents

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met
- Claim exceeds maximum dosing limitation for the following:

Drug Description	Generic Equivalent	Max Dosing Limitation
ACTONEL 5 MG TABLET	RISEDRONATE	1 tablet per day
ACTONEL 30 MG TABLET	RISEDRONATE	1 tablet per day
ACTONEL 35 MG TABLET	RISEDRONATE	1 tablet per week
ACTONEL 150 MG TABELT	RISEDRONATE	1 tablet per month
ATELVIA DR 35 MG TABLET	RISEDRONATE	1 tablet per week
BINOSTO 70 MG	ALENDRONATE	1 tablet per week
BONIVA 150 MG TABLET	IBANDRONATE	1 tablet per month
FOSAMAX 5 MG	ALENDRONATE	1 tablet per day
FOSAMAX 10 MG	ALENDRONATE	1 tablet per day
FOSAMAX 35 MG	ALENDRONATE	1 tablet per week
FOSAMAX 40 MG	ALENDRONATE	1 tablet per day
FOSAMAX 70 MG	ALENDRONATE	1 tablet per week
FOSAMAX 70 MG/75 ML	ALENDRONATE	75 mL per week
FOSAMAX PLUS D 70 MG/2,800 IU	ALENDRONATE/VITAMIN D3	1 tablet per week
FOSAMAX PLUS D 70 MG/5,600 IU	ALENDRONATE/VITAMIN D3	1 tablet per week

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

References

1. Evidence-Based Medicine and Fiscal Analysis: "Bone Deossification Suppression Agents – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; June 2021.
2. Evidence-Based Medicine Analysis: "Bone Deossification Suppression Agents (Including Calcitonin)", UMKC-DIC; March 2021.
3. USPDI, Micromedex; 2021.
4. Facts and Comparisons eAnswers (online); 2021 Clinical Drug Information, LLC.
5. Binosto [package insert]. Herndon, VA: Ascend Therapeutics; March 2021.
6. Fosamax [package insert]. Whitehouse Station, NJ: Merck & Co Inc; August 2019.
7. Fosamax plus D [package insert]. Whitehouse Station, NJ: Merck & Co Inc; August 2019.
8. Etidronate Disodium [package insert]. Morgantown, WV: Mylan Pharmaceuticals, Inc.; 2010.
9. Boniva [package insert]. South San Francisco, CA: Genentech USA, Inc.; October 2020.
10. Actonel [package insert]. Madison, NJ: Allergan USA, Inc.; November 2019.
11. Atelvia [package insert]. Madison, NJ: Allergan USA, Inc.; August 2020.
12. Calcitonin salmon nasal spray [package insert]. Weston, FL: Apotex Inc.; November 2017.

SmartPA PDL Proposal Form

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.